Document And Entity Information Document Information [Table] Document Information [Line Items] Document Type Document Annual Report Document Period End Date Entity File Number Entity Registrant Name Entity Incorporation, State or Country Code Entity Tax Identification Number Entity Address, Address Line One Entity Address, City or Town Entity Address, State or Province Entity Address, Postal Zip Code City Area Code Local Phone Number Title of 12(g) Security Security Exchange Name Entity Well-known Seasoned Issuer Entity Voluntary Filers Entity Current Reporting Status Entity Interactive Data Current Entity Filer Category Entity Small Business Entity Emerging Growth Company ICFR Auditor Attestation Flag Document Financial Statement Error Correction [Flag] Entity Shell Company Entity Common Stock, Shares Outstanding Entity Public Float Entity Central Index Key Current Fiscal Year End Date Document Fiscal Year Focus Document Fiscal Period Focus Amendment Flag Trading Symbol Document Transition Report Auditor Firm ID Auditor Name Auditor Location Balance Sheet Statement [Table] Class of Stock [Axis] Class of Stock [Domain] Represent information pertaining to Series A Preferred stock Series A Convertible Preferred Stock [Member] Series A Preferred Stock Series A convertible preferred stock Related Party [Axis] Related Party [Domain] Nonrelated Party [Member] Nonrelated party Related Party [Member] Related party Statement [Line Items] Statement Assets [Abstract] ASSETS Assets, Current [Abstract] CURRENT ASSETS: Cash and Cash Equivalents, at Carrying Value Cash and cash equivalents Prepaid Expense, Current Prepaid expenses Assets, Current Total current assets Property, Plant and Equipment, Net Property and equipment, net Property and Equipment, Net Intangible Assets, Net (Excluding Goodwill) Intangible assets, net Intangible Assets, Net Total Other Assets [Abstract] OTHER ASSETS This fact represents service agreements. Service Agreements Service agreements Assets Total assets Liabilities and Equity [Abstract] LIABILITIES AND STOCKHOLDERS' EQUITY Liabilities [Abstract] CURRENT LIABILITIES: Accounts Payable, Related Parties, Current Accounts Payable - Related Party Accounts payable Accrued Liabilities, Current Accrued expenses Accrued expenses Liabilities, Current Total current liabilities Commitments and Contingencies. COMMITMENTS AND CONTINGENCIES (NOTE 11) Stockholders' Equity Attributable to Parent [Abstract] STOCKHOLDERS' EQUITY: Preferred Stock, Value, Issued Series A convertible preferred stock, $0.00001 par value, 10,000,000 shares designated, 908,809 and 905,717 shares issued and outstanding, at June 30, 2026 and 2025, respectively. (Note 9) Common Stock, Value, Issued Common stock, $0.00001 par value; 150,000,000 shares authorized, 23,008,308 and 16,606,832 shares issued and outstanding at June 30, 2026 and 2025, respectively. (Note 8) Additional Paid in Capital Additional paid-in capital Retained Earnings (Accumulated Deficit) Accumulated deficit Accumulated deficit Stockholders' Equity Attributable to Parent Ending Balance Beginning Balance Total stockholders' equity Liabilities and Equity Total liabilities and stockholders' equity Preferred Stock, Par or Stated Value Per Share Preferred stock, par value (in dollars per share) Preferred stock, par value (in dollars per share) Preferred Stock, Shares Authorized Preferred stock, shares authorized Preferred Stock, Shares Issued Preferred Stock, Shares Issued Preferred stock, shares issued Preferred Stock, Shares Outstanding Preferred stock, shares outstanding Common Stock, Par or Stated Value Per Share Common stock, par value (in dollars per share) Common stock, par value (in dollars per share) Common Stock, Shares Authorized Common stock, shares authorized Common Stock, Shares, Issued Common stock, shares issued Common Stock, Shares, Outstanding Common stock, shares, outstanding Statements of Operations Operating Expenses [Abstract] OPERATING EXPENSES Research and Development Expense Research and Development Costs - Related Party Research and development General and Administrative Expense General and administrative Operating Expenses Total operating expenses Operating Income (Loss) LOSS FROM OPERATIONS Nonoperating Income (Expense) [Abstract] OTHER INCOME (EXPENSE): Other Nonoperating Income (Expense) Interest income Interest Expense, Nonoperating Interest expense Nonoperating Income (Expense) Other income, net Net loss NET LOSS Net loss Earnings Per Share [Abstract] Net loss per common share/Weighted average common shares Earnings Per Share, Basic Net loss per common share - basic (in dollars per share) Earnings Per Share, Diluted Net loss per common share - diluted (in dollars per share) Weighted Average Number of Shares Outstanding, Basic and Diluted Weighted average common shares - basic (in shares) Weighted Average Number of Shares Outstanding, Diluted Weighted average common shares - diluted (in shares) Statement of Changes in Stockholders' Equity Equity Components [Axis] Equity Component [Domain] Common Stock Common Stock Additional Paid-in Capital Accumulated Deficit Shares, Outstanding Ending Balance (in shares) Beginning Balance (in shares) Stock Issued During Period, Value, New Issues Proceeds from sale of common stock in connection with equity financings net of issuance costs Stock Issued During Period, Shares, New Issues Proceeds from sale of common stock in connection with equity financings net of issuance costs (in shares) Issuance of shares Value of preferred stock shares issued during period as employee stock compensation. Series A Preferred Shares Issued During Period Employee Stock Compensation Value Issued Series A preferred stock issued for employee stock compensation Number of series A preferred stock issued during period as employee stock compensation. Series A Preferred Shares Issued During Period Employee Stock Compensation Shares Issued Series A preferred stock issued for employee stock compensation (in shares) Equity impact of the value of new stock and warrants issued during the period. Stock Issued During Period, Shares And Warrants, Value, New Issues Proceeds from Registered Direct Offering of common stock and warrants net of financing cost of $893,243 (See Note 8) Number of new stock and warrants issued during the period. Stock Issued During Period, Shares And Warrants, New Issues Proceeds from Registered Direct Offering of common stock and warrants net of financing cost of $893,243 (See Note 8) (in shares) Value of stock issued during the period as a compensation for consulting and legal services. Stock Issued During July Value Issued For Share Based Compensation Consulting And Legal Service One Common stock issued for consulting and legal services rendered Number of shares issued during the period as a compensation for consulting and legal services. Stock Issued During July Share Issued For Share Based Compensation Consulting And Legal Service One Common stock issued for consulting and legal services rendered (in shares) Value of stock issued during the period as a compensation for consulting and legal services. Stock Issued During Shares Issued For Share Based Compensation Consulting And Legal Services Warrants issued to Scientific Advisory Board Stock Issued During Period, Value, Employee Benefit Plan Common stock issued for employee compensation Stock Issued During Period, Shares, Employee Benefit Plan Common stock issued for employee compensation (in shares) The amount represents the stock issued during the period for payment of director fees. Stock Issued For Payment Of Director Fees Value Common stock issued for Directors fees The amount represents the stock issued during the period for payment of director fees. Stock Issued For Payment Of Director Fees Shares Common stock issued for Directors fees (in shares) Proceeds from Issuance or Sale of Equity Stock issuance costs Amount of expense for cost associated with issuance of stock and warrants. Stock And Warrants Issuance Costs Stock and warrants issuance costs Statements of Cash Flows Net Cash Provided by (Used in) Operating Activities [Abstract] CASH FLOWS FROM OPERATING ACTIVITIES: Net Income (Loss), Including Portion Attributable to Noncontrolling Interest Net loss Adjustments to Reconcile Net Income (Loss) to Cash Provided by (Used in) Operating Activities [Abstract] Adjustments to reconcile net loss to net cash used in operating activities Amount of preferred shares issued as compensation by the entity during the period. Preferred Shares Issued As Compensation Preferred shares issued as compensation Issuance of Stock and Warrants for Services or Claims Common shares issued as compensation and for services Common shares issued as compensation and for services Adjustment of Warrants Granted for Services Warrants granted to Scientific Advisory Board Depreciation Depreciation expense Depreciation Amortization of Intangible Assets Amortization Amortization expense Increase (Decrease) in Operating Capital [Abstract] Changes in operating assets and liabilities: Increase (Decrease) in Prepaid Expense Prepaid expenses Increase (Decrease) in Other Noncurrent Assets Other assets Increase (Decrease) in Accounts Payable, Trade Accounts payable Increase (Decrease) in Accounts Payable, Related Parties Accounts payable - related parties Increase (Decrease) in Other Accrued Liabilities Accrued expenses Net Cash Provided by (Used in) Operating Activities Net cash used in operating activities NET CASH USED IN OPERATING ACTIVITIES Net Cash Provided by (Used in) Investing Activities [Abstract] CASH FLOWS FROM INVESTING ACTIVITIES: Payments to Acquire Property, Plant, and Equipment Purchase of property and equipment Net Cash Provided by (Used in) Investing Activities NET CASH USED IN INVESTING ACTIVITIES Net Cash Provided by (Used in) Financing Activities [Abstract] CASH FLOWS FROM FINANCING ACTIVITIES: Proceeds from Issuance of Common Stock Net proceeds from sale of common stock Gross proceeds The net cash inflow from issuance of common stock and warrants after issuance costs. Net Proceeds from Issuance of Common Stock and Common Stock Warrants Net proceeds from the sale of common stock and common stock warrants Net Cash Provided by (Used in) Financing Activities NET CASH PROVIDED BY FINANCING ACTIVITIES Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents, Period Increase (Decrease), Excluding Exchange Rate Effect NET CHANGE IN CASH AND CASH EQUIVALENTS Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents Cash and cash equivalents at end of period Cash and cash equivalents at beginning of period Supplemental Cash Flow Information [Abstract] SUPPLEMENTAL DISCLOSURE OF CASH FLOWS INFORMATION: Interest Paid, Net Interest paid Organization and Nature of Business Nature of Operations [Text Block] Organization and Nature of Business N/a. Liquidity and Going Concern Liquidation Basis of Accounting [Text Block] Liquidity and Going Concern Summary of Significant Accounting Policies Significant Accounting Policies [Text Block] Summary of Significant Accounting Policies Related Party Transactions Related Party Transactions Disclosure [Text Block] Related Party Transactions Property and Equipment Property, Plant and Equipment Disclosure [Text Block] Property and Equipment Intangible Assets Intangible Assets Disclosure [Text Block] Intangible Assets Accrued expenses Accounts Payable and Accrued Liabilities Disclosure [Text Block] Accrued expenses Equity Transactions Stockholders' Equity Note Disclosure [Text Block] Equity Transactions Common Stock Warrants Disclosure of Compensation Related Costs, Share-based Payments [Text Block] Common Stock Warrants Income Tax Provision Income Tax Disclosure [Text Block] Income Tax Provision Commitments and Contingencies Commitments and Contingencies Disclosure [Text Block] Commitments and Contingencies Subsequent Events Subsequent Events [Text Block] Subsequent Events Basis of Accounting, Policy [Policy Text Block] Basis of Presentation Earnings Per Share, Policy [Policy Text Block] Net Loss per Common Share Use of Estimates, Policy [Policy Text Block] Use of Estimates Fair Value of Financial Instruments, Policy [Policy Text Block] Fair Value of Financial Instruments Impairment or Disposal of Long-Lived Assets, Policy [Policy Text Block] Long-Lived Assets Cash and Cash Equivalents, Policy [Policy Text Block] Cash and Cash Equivalents Property, Plant and Equipment, Policy [Policy Text Block] Property and Equipment Goodwill and Intangible Assets, Intangible Assets, Policy [Policy Text Block] Intangible Assets Research and Development Expense, Policy [Policy Text Block] Research and Development Share-based Compensation, Option and Incentive Plans Policy [Policy Text Block] Stock-Based Compensation Income Tax, Policy [Policy Text Block] Income Taxes Concentration Risk, Credit Risk, Policy [Policy Text Block] Concentrations of Risk Segment Reporting, Policy [Policy Text Block] Segment and geographic information New Accounting Pronouncements, Policy [Policy Text Block] Recently Issued Accounting Pronouncements and Recently Adopted Accounting Standards Schedule of Antidilutive Securities Excluded from Computation of Earnings Per Share [Table Text Block] Schedule of potentially outstanding dilutive common shares excluded from the diluted net loss per common share calculation Schedule of Related Party Transactions [Table Text Block] Summary of related party Property, Plant and Equipment [Table Text Block] Schedule of property and equipment Schedule of Finite-Lived Intangible Assets [Table Text Block] Schedule of intangible assets Schedule of Accrued Liabilities [Table Text Block] Schedule of accrued expenses Schedule of Stock by Class [Table] Sale of Stock [Axis] Sale of Stock [Domain] Represents information pertaining to ATM offering. ATM Offering [Member] ATM Offering Represents information pertaining to registered direct offering. Registered Direct Offering [Member] Registered Direct Offering Registered Direct Offering Class of Stock [Line Items] Equity Transactions Tabular disclosure of proceeds from the sale of stock. Schedule of Proceeds From Sale of Stock [Table Text Block] Schedule of proceeds from sale of stock Schedule of Stockholders Equity [Table Text Block] Schedule of estimation the fair value of the warrants granted Schedule of Share-based Compensation Arrangements by Share-based Payment Award [Table] Share-based Compensation Arrangement by Share-based Payment Award [Line Items] Common Stock Warrants Schedule of Stockholders' Equity Note, Warrants or Rights [Table Text Block] Schedule of common stock warrants activity Schedule of Deferred Tax Assets and Liabilities [Table Text Block] Schedule of components of the Company's deferred tax assets and liabilities Schedule of Effective Income Tax Rate Reconciliation [Table Text Block] Schedule of income tax expense differed from the amounts computed by applying the U.S. federal income tax rate Number of Reportable Segments Number of reportable segments Financial Condition [Table] Subsequent Event Type [Axis] Subsequent Event Type [Domain] Subsequent event Subsequent event Subsequent Events Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table. Financial Condition [Line Items] Liquidity and Going Concern Revenue from Contract with Customer, Including Assessed Tax Revenue Sale of Stock, Consideration Received Per Transaction Net proceeds from issuance of common stock Net proceeds from issuance of common stock Liabilities Liabilities Line of Credit Facility, Current Borrowing Capacity Line of credit Sale of Stock, Consideration Received on Transaction Net proceeds Warrants and Rights Outstanding, Term Warrants expiry term Class of Warrant or Right, Exercise Price of Warrants or Rights Exercise price (in dollars per share) Accounting Policies [Table] Financial Instrument [Axis] Financial Instruments [Domain] Represents information pertaining to warrants excluding participating warrants. Warrants Excluding Participating Warrants [Member] Warrants Represents information pertaining to participating warrants. Participating Warrants [Member] Warrants (Participating Securities) Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table. Accounting Policies [Line Items] Summary of Significant Accounting Policies Antidilutive Securities Excluded from Computation of Earnings Per Share, Amount Potentially outstanding dilutive common shares Number of potentially dilutive common shares Stockholders' Equity Note, Stock Split, Conversion Ratio Reverse stock split Represent of percentage of change of control Percentage Of Change Of Control Percentage of change of control Property, Plant and Equipment [Table] Property, Plant and Equipment, Type [Axis] Property, Plant and Equipment, Type [Domain] GMP facility GMP facility Furniture and fixtures Furniture and fixtures Lab equipment Lab equipment Office equipment Office equipment Property, Plant and Equipment [Line Items] Property, plant and equipment Property, Plant and Equipment, Useful Life Property and equipment, estimated useful lives Intangible Asset, Finite-Lived [Table] Range [Axis] Range [Domain] Minimum Minimum Maximum Maximum Intangible Asset, Finite-Lived [Line Items] Finite-Lived Intangible Asset, Useful Life Economic lives of the assets Unrecognized Tax Benefits Unrecognized tax benefits Schedule of Related Party Transactions, by Related Party [Table] Counterparty Name [Axis] Counterparty Name [Domain] Represents the information relating to Theracour Pharma Inc. TheraCour Pharma Inc [Member] TheraCour Pharma Inc Related Party Transaction [Line Items] Related Party Transaction Property, Plant and Equipment, Additions Property and Equipment Represents the information pertaining to Karveer Meditech, Pvt., Ltd. Karveer Meditech, Pvt., Ltd [Member] KMPL Credit Facility [Axis] Credit Facility [Domain] Line of Credit [Member] Line of credit agreement Title of Individual [Axis] Relationship to Entity [Domain] Represent information pertaining to Dr. Anil Diwan member. Dr. Anil Diwan Dr. Anil Diwan Carrying value as of the balance sheet date of the obligations incurred through Clinical trials. Used to reflect the current portion of the liabilities (The amount has been recorded within accrued expenses in the accompanying balance sheet). Accrued Clinical Trial Costs Clinical trial Costs Accrued - Related Party The cash outflow for clinical trial costs. Payment of Clinical Trial Costs Payment of clinical trial costs The percentage of direct costs. Percentage of Direct Costs Percentage of direct costs Other General and Administrative Expense Other general and administrative expense Carrying amount of current accounts payable due to a related party representing amounts originally payable to another related party that were assigned to the related party in satisfaction of disbursements made on behalf of another related party. Accounts Payable Assigned From Another Related Party, Current Carrying amount of current accounts payable Amount of current accounts payable due to a related party representing obligations originally payable to another related party that were assigned to the related party in satisfaction of disbursements made on behalf of the original related party. Accounts Payable Assigned To Another Related Party, Current Amount of current accounts payable Royalty expense calculated as a percentage of net sales. Percentage of Net Sales Allocated for Royalty Payments Percentage of net sales allocated for royalty payments (in percent) Amount for accounts payable offset by advance. Accounts Payable Offset By Advance Accounts payable offset by advance Accrued Royalties Accrued royalties Line of Credit Facility, Maximum Borrowing Capacity Line of Credit Facility, maximum borrowing capacity Line of Credit Facility, Interest Rate During Period Fixed rate of interest on the amount drawn under the line of credit facility Long-Term Line of Credit Line of credit Line of Credit Facility, Expiration Date Maturity of the Company's line of Credit Notes Payable, Related Parties, Current Drew down amount Leasehold Improvements, Gross GMP Facility Land Land Gross amount, at the balance sheet date, of office equipment. Office Equipment Gross Office Equipment Furniture and Fixtures, Gross Furniture and Fixtures Fixtures and Equipment, Gross Lab Equipment Property, Plant and Equipment, Gross Total Property and Equipment Accumulated Depreciation, Depletion and Amortization, Property, Plant, and Equipment Less Accumulated Depreciation Amount of fully depreciated property, plant and equipment that was retired, disposed of, or removed from service during the reporting period. Property, Plant and Equipment, Fully Depreciated Cost Property plant and equipment fully depreciated cost Gain (Loss) on Disposition of Property Plant Equipment Gain (loss) on disposition of property plant equipment The disclosure information about trademark and patents. Schedule Of Trademarks And Patents [Table] Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table. Trademarks and Patents [Line Items] Intangible Assets Finite-Lived Intangible Assets, Gross Intangible Assets Indefinite-Lived Intangible Assets (Excluding Goodwill) Indefinite Lived intangible Assets Intangible Assets, Gross (Excluding Goodwill) Intangible Assets, Total Finite-Lived Intangible Assets, Accumulated Amortization Less Accumulated Amortization Finite-Lived Intangible Assets, Net Intangible Assets, Net Employee-related Liabilities, Current Personnel and compensation costs Accrued Professional Fees, Current Consultant Carrying value as of the balance sheet date of the obligations incurred through Clinical trials. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer). Accrued Clinical Trial Costs, Current Other Series A Preferred stock [Member] Series A Preferred stock Series A Preferred Stock Class of Warrant or Right [Axis] Class of Warrant or Right [Domain] Represents the component of equity related to pre-funded warrants issued by the entity. Pre Funded Warrants [Member] Pre-Funded Warrants Represents information pertaining to Series A warrants. Series Warrants [Member] Series A Warrants Represents information pertaining to Series B warrants. Series B Warrants [Member] Series B Warrants Represents information pertaining to common warrants. Common Warrants [Member] Common Warrants Warrants [Member] Warrants Director Director Employee compensation Employee compensation Represents information relating to consulting services. Consulting services Consulting services This member stands for the Company's founder, Chairman and President, Mr. Anil Diwan. Founder, Chairman, President Founder, Chairman and President Antidilutive Securities [Axis] Antidilutive Securities, Name [Domain] Private Placement [Member] Private placement Grantee Status [Axis] Grantee Status [Domain] Share-Based Payment Arrangement, Employee [Member] Employees Share-Based Payment Arrangement, Nonemployee [Member] Share-based payment arrangement, nonemployee Estimated period of extension term of employee agreement for share based compensation arrangement by share based payment award, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days. Share-Based Compensation Arrangement by Share-Based Payment Award, Employee Agreement, Term of Extension Employment agreement extension term (in years) Stock Issued During Period, Shares, Share-based Compensation, Gross Shares granted The number of shares vest on quarterly installments for share-based compensation. Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Shares Vest on Quarterly Installments Number of shares vest on quarterly installments The amount of Non Cash Compensation Expenses. Non Cash Compensation Expenses Non-cash compensation expense The total value of shares issued or to be sold by the entity in the stock transaction. Sale of Stock, Aggregate Value of Shares Issued in Transaction Aggregate offering price Shares Issued, Price Per Share Average price The number of shares to be issued pursuant to agreement. Number Of Shares To Be Issued Number of shares to be issued (in shares) Share Price Share price Public offering price (in dollars per share) Class of Warrant or Right, Number of Securities Called by Warrants or Rights Warrants to purchase additional shares (in shares) Number of shares issuable upon exercise of warrants issued Price per share at which was offered in a registered direct offering. Class of Warrant or Right, Issue Price of Warrants or Rights Warrant issued price (in dollars per share) Class of Warrant or Right, Number of Securities Called by Each Warrant or Right Number of shares issuable upon exercise of each warrants issued Represents the period after which the warrants become exercisable. Period After Which Warrants Exercisable Period after which warrants become exercisable The cash inflow from issuance of common stock and warrants. Proceeds from Issuance of Common Stock and Warrants Gross proceeds The net cash inflow from issuance of common stock and warrants after issuance costs. Net Proceeds from Issuance of Common Stock and Warrants Net proceeds Proceeds from Warrant Exercises Proceeds from warrants exercise Number of warrants exercised during the current period. Stock Issued During Period, Shares, Warrants Exercised Warrants exercised The number of common stock to be issued upon exercise of warrants. Number Of Common Stock To Be Issued Upon Conversion Of Warrants Number of fully vested warrants granted to purchase shares of common stock Allocated Share-based Compensation Expense Non-cash compensation expense recognized Share-based Compensation Stock-based compensation expense Represents the number of common shares authorized during the period of time. Common Stock, Number of Shares Authorized During The Period Number of shares authorized Disclosure of information about sale of stock made by the entity to investor outside consolidated group by type of sale. Sale of Stock By Entity, Type [Table] Disclosure of information about sale of stock made by the entity to investor outside consolidated group by type of sale. Sale of Stock By Entity, Type [Line Items] Equity Transactions Payments of Stock Issuance Costs Less: Offering Costs and Expense Less: offering costs and expenses Represents information pertaining to November 10, 2025 registered direct offering. Registered Direct Offering, November 10, 2025 [Member] November 10, 2025 Registered Direct Offering Represents information pertaining to May 15, 2026 registered direct offering. Registered Direct Offering, May 15, 2026 [Member] May 15, 2026 Registered Direct Offering Representing the information pertaining to scientific advisory board. Scientific Advisory Board Scientific Advisory Board Share-based Compensation Arrangement by Share-based Payment Award, Fair Value Assumptions, Expected Term Expected life (year) Share-based Compensation Arrangement by Share-based Payment Award, Fair Value Assumptions, Expected Volatility Rate, Minimum Expected volatility, minimum Share-based Compensation Arrangement by Share-based Payment Award, Fair Value Assumptions, Expected Volatility Rate, Maximum Expected volatility, maximum Share-based Compensation Arrangement by Share-based Payment Award, Fair Value Assumptions, Expected Dividend Rate Expected annual rate of quarterly dividends Share-based Compensation Arrangement by Share-based Payment Award, Fair Value Assumptions, Risk Free Interest Rate, Minimum Risk-free rate(s), minimum Share-based Compensation Arrangement by Share-based Payment Award, Fair Value Assumptions, Risk Free Interest Rate, Maximum Risk-free rate(s), maximum Represents the information pertaining to Stock Warrants. Stock Warrants [Member] Common Stock Warrants Share-based Compensation Arrangement by Share-based Payment Award, Options, Outstanding, Number Number of Shares, Outstanding and exercisable (in shares) Number of Shares, Outstanding and exercisable (in shares) Share-based Compensation Arrangement by Share-based Payment Award, Options, Grants in Period, Gross Number of Shares, Granted as compensation (in shares) Number of share options (or share units) issued to investors during the period. Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Issued To Investors Number of Shares, Issued to investors (in shares) Share-based Compensation Arrangement by Share-based Payment Award, Options, Expirations in Period Number of Shares, Expired (in shares) Share-based Compensation Arrangement by Share-based Payment Award, Options, Outstanding, Weighted Average Exercise Price Weighted Average Exercise Price per share, Outstanding and exercisable (dollars per share) Weighted Average Exercise Price per share, Outstanding and exercisable (dollars per share) Share-based Compensation Arrangements by Share-based Payment Award, Options, Grants in Period, Weighted Average Exercise Price Weighted Average Exercise Price per share, Granted (dollars per share) Weighted average per share amount at which issuer issued to investors can acquire shares of common stock by exercise of options. Share-Based Compensation Arrangements by Share-Based Payment Award, Options, Issued To Investors, Weighted Average Exercise Price Weighted Average Exercise Price per share, Issued to investors (dollars per share) Share-based Compensation Arrangements by Share-based Payment Award, Options, Expirations in Period, Weighted Average Exercise Price Weighted Average Exercise Price per share, Expired (dollars per share) Weighted average remaining contractual term for vested portions of options granted, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days. Share based Compensation Arrangement By Share based Payment Award Options Grants In Period Weighted Average Remaining Contractual Term Weighted Average Remaining Contractual life Term (years), Granted Weighted average remaining contractual term for vested portions of options issued to investors, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days. Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Issued To Investors, Weighted Average Remaining Contractual Term Weighted Average Remaining Contractual Term (years), Issued to investors Share-based Compensation Arrangement by Share-based Payment Award, Options, Outstanding, Weighted Average Remaining Contractual Term Weighted Average Remaining Contractual life Term (years), Outstanding and exercisable Share-based Compensation Arrangement by Share-based Payment Award, Options, Outstanding, Intrinsic Value Aggregate Intrinsic Value, Outstanding and exercisable (in dollars) The grant-date intrinsic value of options granted during the reporting period as calculated by applying the disclosed option pricing methodology. Share Based Compensation Arrangement By Share Based Payment Award Options Grants In Period Intrinsic Value Aggregate Intrinsic Value, Granted (in dollars) Vesting [Axis] Vesting [Domain] Representing the member information pertaining to June 30, 2027. June 30, 2027 [Member] June 30, 2027 Representing the member information pertaining to June 30, 2028. June 30, 2028 [Member] June 30, 2028 Representing the member information pertaining to June 30, 2029. June 30, 2029 [Member] June 30, 2029 Representing the member information pertaining to June 30, 2030. June 30, 2030 [Member] June 30, 2030 Representing the member information pertaining to June 30, 2031. June 30, 2031 [Member] June 30, 2031 Aggregate amount of warrants are exercisable during the reporting period. Warrants Exercisable Warrants exercisable Deferred Tax Assets, Operating Loss Carryforwards Net operating loss Deferred Tax Assets, Tax Credit Carryforwards, Research Research and development credit Amount before allocation of valuation allowances of deferred tax asset attributable to capitalized research and expenses tax credit carryforwards. Deferred Tax Assets, Tax Credit Carryforwards, Research & Expenses Capitalized IRC Sec.174 R&E Capitalization Deferred Tax Assets, Other Other Deferred Tax Assets, Gross Gross deferred tax assets Total gross deferred tax assets Deferred Tax Assets, Valuation Allowance Less: valuation allowance Deferred tax assets, valuation allowance Deferred Tax Assets, Net of Valuation Allowance Net deferred tax asset Income Tax Expense (Benefit), Effective Income Tax Rate Reconciliation, Amount [Abstract] Income tax expense (benefit), effective income tax rate reconciliation, amount Income (Loss) from Continuing Operations before Income Taxes, Noncontrolling Interest Net loss before income taxes Effective Income Tax Rate Reconciliation at Federal Statutory Income Tax Rate, Amount US federal statutory tax rate Effective Income Tax Rate Reconciliation, Tax Credit, Amount [Abstract] Tax credits Effective Income Tax Rate Reconciliation, Tax Credit, Research, Amount R&D Credit Effective Income Tax Rate Reconciliation, Change in Deferred Tax Assets Valuation Allowance, Amount Changes in valuation allowance Effective Income Tax Rate Reconciliation, Tax Contingency, Amount Forgone benefit on federal tax NOLs Effective Income Tax Rate Reconciliation, Nondeductible Expense, Research and Development, Amount Forgone benefit on federal R&D Credit Effective Income Tax Rate Reconciliation, Other Adjustments, Amount Other adjustments - Other Income Tax Expense (Benefit) Effective tax rate Tax Jurisdiction of Domicile [Extensible Enumeration] Effective Income Tax Rate Reconciliation, Percent [Abstract] Effective income tax rate reconciliation, percent Effective Income Tax Rate Reconciliation, at Federal Statutory Income Tax Rate, Percent US federal statutory tax rate (in percent) Federal Statutory Rate Effective Income Tax Rate Reconciliation, State and Local Income Taxes, Percent State income taxes, net of federal income tax effect (in percent) State tax rate Effective Income Tax Rate Reconciliation, Tax Credit, Percent [Abstract] Tax credits (in percent) Effective Income Tax Rate Reconciliation, Tax Credit, Research, Percent R&D Credit (in percent) R&D Credit (in percent) Effective Income Tax Rate Reconciliation, Change in Deferred Tax Assets Valuation Allowance, Percent Changes in valuation allowance (in percent) Valuation allowance Effective Income Tax Rate Reconciliation, Tax Contingency, Percent Forgone benefit on federal tax NOLs (in percent) Effective Income Tax Rate Reconciliation, Nondeductible Expense, Research and Development, Percent Forgone benefit on federal R&D Credit (in percent) Effective Income Tax Rate Reconciliation, Other Adjustments, Percent Other adjustments - Other (in percent) Other adjustments - Other (in percent) Effective Income Tax Rate Reconciliation, Percent Effective tax rate (in percent) Effective Income Tax Rate Reconciliation, Nondeductible Expense, Percent Nondeductible tax rate Presentation of information about income tax provision. Income Tax Provision [Table] Tax Credit Carryforward [Axis] Tax Credit Carryforward, Name [Domain] Research and development credit carryforwards Research and development credit carryforwards No definition available. Income Tax Provision [Line Items] Income Tax Provision Current Income Tax Expense (Benefit) Current tax expense Income Tax Paid, after Refund Received Cash payments Income Tax Paid, Federal, after Refund Received Income tax paid, federal Income Tax Paid, State and Local, after Refund Received Income tax paid, state and local Income Tax Paid, Foreign, after Refund Received Income tax paid, foreign Operating Loss Carryforwards Operating loss carryforwards Amount of operating losses generated during the period that can be carried forward indefinitely. Operating Loss That Can Be Carried Forward Indefinitely Net operating loss that can be carried forward indefinitely Percentage of net operating losses incurred in income tax payable. Net Operating Losses Incurred In Income Tax Payable, Net Net operating losses income tax payable Tax Credit Carryforward, Amount Tax credit carryforwards The disclosure information about commitment and contingencies. Commitments and Contingencies [Table] Chief Financial Officer [Member] Chief Financial Officer Vice President [Member] Vice President The line item information about commitment and contingencies. Commitments and Contingencies [Line Items] Commitments and Contingencies Amount of annual base salary as agreed to be paid by the company under the employment agreement. Base Salary Base Salary The amount of value assigned to term life insurance policy. Term Life Insurance Policy Value Term life insurance value The amount of value assigned to the company on term life insurance policy. Term Life Insurance Policy Value Assigned To Company Term life insurance value assigned to company Deferred Compensation Arrangement with Individual, Shares Authorized for Issuance Number of shares granted Date the employment agreement was made. Employment Agreement Term Employment agreement term Total number of additional nonredeemable preferred shares issued to shareholders. Additional Preferred Stock Shares Issued Additional preferred stock shares issued Total number of additional common shares of an entity that have been sold or granted to shareholders. Additional Common Stock Shares Issued Additional common stock shares issued This element represents the certain amount of estimated salary increase in their base. Increase In Base Salary Increase In base salary It represents the amount of stock issued during period, value, new issues, cash upon completion of phase I clinical trials. Stock Issued During Period Value New Issues Cash Upon Completion Of Phase 1 Clinical Trials Cash upon completion of Phase I Clinical Trials It represents the amount of stock issued during period, value, new issues, cash upon completion of phase II clinical trials. Stock Issued During Period Value New Issues Cash Upon Completion Of Phase 2 Clinical Trials Cash upon completion of Phase II Clinical Trials It represents the amount of stock issued during period, value, new issues, cash upon completion of phase III clinical trials. Stock Issued During Period Value New Issues Cash Upon Completion Of Phase 3 Clinical Trials Cash upon completion of Phase III Clinical Trials The number of shares issuable upon execution of agreement. Number Of Shares Issuable Upon Execution Of Agreement Number of shares issuable upon execution of agreement The threshold period for issuance of shares upon execution of agreement. Threshold Period For Issuance Of Shares Upon Execution Of Agreement Threshold Period for Issuance of Shares Upon Execution of Agreement It represents the amount of stock issued during period, value, new issues, upon initiation of phase I clinical trials. Stock Issued During Period Value New Issues Initiation Of Phase 1 Clinical Trials Stock Issued During Period Value New Issues Initiation Of Phase1 Clinical Trials It represents the amount of stock issued during period, value, new issues, upon initiation of phase III clinical trials. Stock Issued During Period Value New Issues Initiation Of Phase 3 Clinical Trials Shares value upon initiation of Phase III Clinical Trials It represents the amount of stock issued during period, value, new issues, upon completion of phase III clinical trials. Stock Issued During Period Value New Issues Completion Of Phase 3 Clinical Trials Shares value upon completion of Phase III Clinical Trials The number of clinical test drug candidates granted for the use, sale, or offer of sale in India. Number of Clinical Test Drug Candidates Granted for the Use, Sale, or Offer of Sale in India Number of clinical test drug candidates granted for the use, sale, or offer of sale in India Percentage of clinical trials manager fee. Percentage of Clinical Trials Fees Percentage of clinical trials fees Percentage of royalty fee paid. Percentage of Royalty Fee Percentage of royalty fee Subsequent Event [Table] Represents the member information pertaining to At The Market Issuance Sales Agreement (the "Sales Agreement"). At the Market Sales Agreement [Member] At The Market Sales Agreement Represents the member information pertaining to July 27, 2026 registered direct offering. July 27, 2026 Registered Direct Offering [Member] July 27, 2026 Registered direct offering Scenario [Axis] Scenario, Unspecified [Domain] Forecast [Member] Forecast Subsequent Event [Line Items] Subsequent Events Percentage of sales agent commission on aggregate gross proceeds. Sales Agent Commission, Percentage Sales agent commission (in percentage) Period for exercise of warrants. Class Of Warrant Or Right, Term Warrant term Threshold restriction period on issue of shares under the securities purchase agreement. Securities Purchase Agreement, Threshold Restriction Period On Shares Issue Securities purchase agreement, threshold restriction period Period for filing of registration statement after closing date under the securities purchase agreement. Securities Purchase Agreement, Registration Statement Filing Period Securities purchase agreement, registration statement filing period The amount of clinical trial costs incurred. Clinical Trail Costs Incurred Clinical trial costs incurred The amount of clinical trial costs. Clinical Trail Cost Clinical trial cost The amount of clinical trial commitment liability. Clinical Trial Commitment Liability Clinical trial commitment liability